CAB ULA

DRUG2 trials

Sponsors

ViiV Healthcare

Conditions

HIV Infections

Phase 1

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults

Active, not recruitingNCT06786520

ViiV HealthcareHIV Infections

Start: 2025-01-17End: 2027-11-08Updated: 2025-06-19

Phase 3

A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

Not yet recruitingNCT07650916

ViiV HealthcareHIV Infections

Start: 2026-06-29End: 2029-09-04Target: 564Updated: 2026-06-23